SCHEMBL2195182

SCHEMBL2195182

CC(C)(C)OC(=O)C=Cc1ncc(Br)cn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
RECQL P46063 1/20 0.33
XPO1 O14980 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
NR1I2 O75469 1/20 0.33
PGR P06401 1/20 0.33
CYP3A4 P08684 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CYP2C9 P11712 1/20 0.33
SLC6A2 P23975 1/20 0.33
TBXAS1 P24557 1/20 0.33
CYP2C19 P33261 1/20 0.33
DRD3 P35462 1/20 0.33
OPRK1 P41145 1/20 0.33
PDE4D Q08499 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195175 1.00 NPC1 (0.33) NPC1RAB9ASMN1; SMN2RECQLXPO1
SCHEMBL2201083 0.81 XPO1 (0.38) NPC1RAB9ASMN1; SMN2XPO1LMNA
SCHEMBL2201082 0.81 XPO1 (0.38) NPC1RAB9ASMN1; SMN2XPO1LMNA
SCHEMBL30288729 0.81 ALDH1A1 (0.38) NPC1RAB9ASMN1; SMN2RECQLXPO1
SCHEMBL16642332 0.81 ALDH1A1 (0.38) NPC1RAB9ASMN1; SMN2RECQLXPO1
SCHEMBL19900075 0.81 ALDH1A1 (0.38) NPC1RAB9ASMN1; SMN2RECQLXPO1
SCHEMBL29385542 0.81 ALDH1A1 (0.38) NPC1RAB9ASMN1; SMN2RECQLXPO1
SCHEMBL15278739 0.78 AAK1 (0.41) NPC1RAB9ASMN1; SMN2RECQLXPO1
SCHEMBL15278595 0.77 AAK1 (0.34) XPO1AAK1ESR1ALDH1A1
SCHEMBL1253843 0.77 KMT2A (0.37) NPC1XPO1AAK1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2398769-A1 NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
US-7977372-B2 Ortho aminoamides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
WO-2010094678-A1 NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100216806-A1 ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE, INC. 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216806-A1 ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER HDAC5, HDAC1, HDAC4 NPC1 3496/4885RAB9A 2658/4885SMN1; SMN2 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.